A Trail of Second-line Chemotherapy Sequential NKG2D CAR-NK Cell Therapy for Pancreatic Cancer

This study tests a new treatment for pancreatic cancer that combines second-line chemotherapy with a special immune cell therapy called CAR-NK cell therapy. The immune cells are engineered to recognize and attack pancreatic cancer cells. The goal is to see whether this combined approach is safe and effective for patients whose cancer has stopped responding to their first treatment. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed pancreatic ductal adenocarcinoma that has progressed after at least one prior treatment - You are in reasonably good physical condition (able to carry out daily activities) - You are expected to live at least 3 more months - You are not pregnant and willing to use contraception **You may NOT be eligible if...** - You are pregnant or breastfeeding - You have an active infection (such as active hepatitis B, HIV, tuberculosis, or COVID-19) - You have had another cancer in the last 5 years (except certain skin or cervical cancers) - You have uncontrolled serious medical conditions Talk to your doctor to see if this trial is right for you.